{"id":69958,"date":"2016-04-26T15:16:25","date_gmt":"2016-04-26T15:16:25","guid":{"rendered":"http:\/\/mostafa.openonline.co.uk\/?guid=ed8e48bdbd5d68ce45155e026bd87e1d"},"modified":"2016-04-26T15:16:25","modified_gmt":"2016-04-26T15:16:25","slug":"news-story-adorial-and-c4x-discovery-combined-firm-powers-drug-discovery","status":"publish","type":"post","link":"https:\/\/mostafa.openonline.co.uk\/?p=69958","title":{"rendered":"News story: Adorial and C4X Discovery: combined firm powers drug discovery"},"content":{"rendered":"
\n

Two business supported by Innovate UK\u2019s Biomedical Catalyst have come together to accelerate commercial and clinical success.<\/p>\n

Adorial Pharma Limited<\/a>, developer of Taxonomy3, a mathematical tool that identifies causes of disease that can be targeted by drugs, has been acquired by C4X Discovery<\/a>, an innovative drug discovery company.<\/p>\n

Adorial\u2019s technology, which is based on novel mathematics, analyses publicly available genetic data sets generated across broad therapeutic areas and is able to mine more genetic insights than conventional methods.<\/p>\n

Technology increases chance of successful drugs<\/h2>\n

These additional insights lead to the discovery and validation of novel drug targets with direct genetic support, which is known to increase the probability of successful drug launch.<\/p>\n

The technique is extremely valuable in the sort of drug discovery work that is undertaken by companies such as Manchester-based C4X Discovery, as they are continually able to focus their drug discovery programmes on areas with greater potential for clinical success.<\/p>\n

The combination with C4X Discovery\u2019s Conformetrix software platform means the new organisation can now find novel proprietary drug targets and rapidly design and discover new drugs for multiple diseases.<\/p>\n

Combined business has powerful drug discovery engine<\/h3>\n

Dr Alun McCarthy, former chief executive of Adorial now vice-president novel target biology and genomics at C4X, said: <\/p>\n

\n

The combination of Adorial\u2019s ability to identify novel drug targets with C4X\u2019s ability to rapidly generate molecules against these targets creates an extremely powerful drug discovery engine.<\/p>\n<\/blockquote>\n

Dr Clive Dix, executive chairman of C4X Discovery, said: <\/p>\n

\n

With Adorial, we now not only have the ability to create the best-in-class molecules against any known therapeutic target using C4XD\u2019s approach to ligand-based drug discovery, but also the ability to identify our own highly relevant and unique targets using Taxonomy3.<\/p>\n<\/blockquote>\n

\n

Find out how Innovate UK is funding innovation in health and life sciences<\/a><\/p>\n<\/div>\n

Funding from Innovate UK supported work of both firms<\/h3>\n

Adorial was founded by Alun and his colleague Dr Olivier Delrieu and was a spin-out in 2014 from PGXIS, a company based in High Wycombe founded in 2007 by Alun.<\/p>\n

Support from Innovate UK allowed PGXIS to build a body of disclosable evidence that Taxonomy3 was an exciting drug discovery technology. <\/p>\n

A subsequent \u00a35000 award from Innovate UK helped the company to optimise its IT systems and make its computer-intensive work five times more cost-effective.<\/p>\n

C4X Discovery won a Biomedical Catalyst funding award in 2014 to look at the feasibility of generating new drug candidates for type 2 diabetes. It won a subsequent Smart award in 2015 to support work to validate a potential target for treatment of type 2 diabetes.<\/p>\n

\n

Find out more about Innovate UK funding opportunities.<\/a><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Two health and life science businesses funded by Innovate UK have come together to create a powerful way to find and design new drugs.<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"_links":{"self":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/69958"}],"collection":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69958"}],"version-history":[{"count":0,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/69958\/revisions"}],"wp:attachment":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69958"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69958"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}